Alnylam Pharmaceuticals reported $125.85M in Sales Revenues for its third fiscal quarter of 2020.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Acadia Pharmaceuticals ACAD:US $ 110M 20M
Alexion Pharmaceuticals ALXN:US $ 1444.6M 0.2M
Alnylam Pharmaceuticals ALNY:US $ 125.85M 21.89M
Amgen AMGN:US $ 6206M 45M
Biocryst Pharmaceuticals BCRX:US $ 2M 2M
Biomarin Pharmaceutical BMRN:US $ 429.48M 72.58M
Bluebird Bio BLUE:US $ 198.89M 177.03M
Dicerna Pharmaceuticals DRNA:US $ 48.88M 8.43M
Gw Pharmaceuticals GWPH:US $ 137.05M 15.76M
Intercept Pharmaceuticals ICPT:US $ 77.25M 4.6M
Neurocrine Biosciences NBIX:US $ 302M 65M
Novartis NVS:US $ 12538M 916M
Ptc Therapeutics PTCT:US $ 75.24M 6.98M
Regeneron Pharmaceuticals REGN:US $ 1952M 123.8M
Sarepta Therapeutics SRPT:US $ 137M 24M
Takeda 4502:JP Y 788935M 12915M
Ultragenyx Pharmaceutical RARE:US $ 61.71M 25.4M
Vertex Pharmaceuticals VRTX:US $ 1524.48M 9.38M
YTE INCY:US $ 688.04M 119.54M